comprehensive -WSS

comprehensive

author：leisure time 2025-08-23 08:56:43 - browse：87

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Syphilis numbers in the United States reach record heights

Wikipedia

WSS

30 years of 'Listening to Prozac'

Boston competes with Raleigh

Disappointing trial forces Pfizer to pivot on obesity medicine plans

What to do when lifesaving products contribute to climate change

Boston competes with Raleigh

30 years of 'Listening to Prozac'

explore

comprehensive

explore

Medicare details structure of new drug price negotiation program

Despite FDA concern, risk that CAR

State Dept. review finds Biden bears some blame for Afghanistan failures

Biogen walks away from Aduhelm, years after polarizing approval

Tori Bowie and the unacceptable rates of Black maternal death

Pediatric cancer treatments threatened by a new FDA policy

Medical records are filled with copy

Readout Newsletter: The latest on Novavax, Merck, Bluebird

New air purifier tech could be key to improving indoor air quality

U.K. Biobank has 500,000 peoples' genome sequences available

hotspot

Fetal surgery at risk from Dobbs and new abortion restrictions

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

The EPA's new lead rule: How one expert crunched the numbers

Medicare drug price negotiation legal challenge met with skepticism

Fetal surgery at risk from Dobbs and new abortion restrictions

Reconstructing family trees of blood cells may help predict disease

Wikipedia

hotspot

Wikipedia

focus